Anavex Life Sciences Corp. (AVXL) shareholders
Close on Nov 18, 2026Market cap $66.69MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 6,671,075 | 8.10% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 4,663,459 | 5.03% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AVXL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,055,628 | 8.69% | $20.86M | +446,010 | 0.00% |
| Vanguard Capital Management LLC | 4,054,589 | 4.37% | $10.50M | +190,639 | 0.00% |
| Two Sigma Investments, LP | 3,046,538 | 3.29% | $7.89M | −201,350 | 0.01% |
| Geode Capital Management, LLC | 2,407,473 | 2.60% | $6.24M | +219,198 | 0.00% |
| State Street Corp | 1,922,770 | 2.07% | $4.98M | −2,589,258 | 0.00% |
| Federated Hermes, Inc. | 1,071,809 | 1.16% | $2.78M | +539,557 | 0.00% |
| Aqr Capital Management LLC | 963,014 | 1.04% | $2.49M | +206,222 | 0.00% |
| Vanguard Portfolio Management LLC | 948,633 | 1.02% | $2.46M | +165,485 | 0.00% |
| Summit Financial, LLC | 909,430 | 0.98% | $2.36M | −31,025 | 0.03% |
| Goldman Sachs Group Inc | 890,634 | 0.96% | $2.31M | +86,199 | 0.00% |
| Marshall Wace, Llp | 889,523 | 0.96% | $2.30M | +470,026 | 0.00% |
| Northern Trust Corp | 784,494 | 0.85% | $2.03M | +59,307 | 0.00% |
| Barclays PLC | 754,226 | 0.81% | $1.95M | +215,949 | 0.00% |
| Charles Schwab Investment Management Inc | 734,795 | 0.79% | $1.90M | −21,763 | 0.00% |
| Bank Of America Corp /De/ | 654,295 | 0.71% | $1.69M | −208,855 | 0.00% |
| Vanguard Fiduciary Trust Co | 621,451 | 0.67% | $1.61M | −25,718 | 0.00% |
| UBS Group AG | 620,374 | 0.67% | $1.61M | +50,418 | 0.00% |
| Private Advisor Group, LLC | 504,000 | 0.54% | $1.31M | +4,300 | 0.01% |
| LPL Financial LLC | 406,109 | 0.44% | $1.05M | −12,531 | 0.00% |
| Stifel Financial Corp | 332,597 | 0.36% | $861.43K | +95,793 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 179 | 37M | 39.9% | 24 / 64 | 56 / 32 | 4M | 7M |
| Q1 2026 | 190 | 40M | 43.1% | 38 / 75 | 46 / 29 | 12M | 5M |
| Q4 2025 | 185 | 38M | 40.9% | 29 / 60 | 55 / 27 | 8M | 2M |
| Q3 2025 | 186 | 33M | 35.5% | 27 / 57 | 49 / 17 | 3M | 2M |
| Q2 2025 | 178 | 33M | 35.1% | 24 / 69 | 34 / 25 | 3M | 2M |
| Q1 2025 | 181 | 31M | 33.9% | 39 / 59 | 43 / 25 | 5M | 3M |
| Q4 2024 | 168 | 30M | 31.9% | 47 / 50 | 39 / 22 | 5M | 2M |
| Q3 2024 | 145 | 27M | 29.2% | 24 / 47 | 29 / 19 | 10M | 3M |
| Q2 2024 | 141 | 27M | 29.0% | 21 / 42 | 43 / 26 | 3M | 9M |
| Q1 2024 | 147 | 33M | 35.2% | 17 / 53 | 43 / 23 | 8M | 2M |
| Q4 2023 | 153 | 26M | 28.5% | 27 / 56 | 36 / 17 | 3M | 2M |
| Q3 2023 | 143 | 25M | 27.0% | 13 / 53 | 47 / 14 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
120 funds held AVXL in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AVXL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,925,439 | 3.16% | $7.58M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,417,982 | 2.61% | $6.26M | 0.01% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 2,045,098 | 2.21% | $5.62M | 0.25% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,041,514 | 1.12% | $2.70M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,002,575 | 1.08% | $2.76M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 737,460 | 0.80% | $1.91M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF | 631,748 | 0.68% | $1.64M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 484,708 | 0.52% | $1.47M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 450,282 | 0.49% | $1.36M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 440,209 | 0.47% | $1.33M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 310,051 | 0.33% | $803.03K | 0.05% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 266,123 | 0.29% | $806.35K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 224,867 | 0.24% | $618.38K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 186,662 | 0.20% | $483.45K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 175,983 | 0.19% | $533.23K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Terrie Kellmeyer | President and CEO, Director | – | – | Nov 6, 2026 |
| Christopher U. Missling | President and CEO, Director | 1,510,165 | 1.63% | Jan 9, 2026 |
| Sandra Boenisch | PFO & Treasurer | 67,963 | 0.07% | Sep 28, 2026 |
| Axel Paeger | Director | – | – | Nov 6, 2026 |
| Peter D.O. Donhauser | Director | 5,000 | 0.01% | Nov 6, 2026 |
| Claus Vander Velden | Director | – | – | Nov 6, 2026 |
| Gautam Patel | Director | – | – | Oct 5, 2026 |
| Adrian Senderowicz | Director | – | – | Oct 5, 2026 |
| Steffen Thomas | Director | 55,000 | 0.06% | Jun 9, 2025 |
| Athanasios Skarpelos | Director | 1,306,458 | 1.41% | Apr 2, 2025 |
| Jiong Ma | Director | – | – | Apr 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christopher U. Missling President and CEO, Director | Sep 11, 2025 | Tax withholding | −145,048 | $9.58 | $1.39M | 1,510,165 |
| Christopher U. Missling President and CEO, Director | Sep 11, 2025 | Option exercise | +187,500 | $5.04 | $945.00K | 1,655,213 |
| Steffen Thomas Director | Jun 5, 2025 | Option exercise | +50,000 | $1.76 | $88.00K | 55,000 |
| Steffen Thomas Director | Jun 5, 2025 | Tax withholding | −11,349 | $7.75 | $87.95K | 43,651 |
| Christopher U. Missling President and CEO, Director | Mar 24, 2025 | Option exercise | +500,000 | $0.92 | $460.00K | 1,750,210 |
| Christopher U. Missling President and CEO, Director | Mar 24, 2025 | Tax withholding | −282,497 | $9.63 | $2.72M | 1,467,713 |
| Peter D.O. Donhauser Director | Jun 14, 2024 | Buy | +2,835 | $3.64 | $10.32K | 5,000 |
| Steffen Thomas Director | May 15, 2024 | Buy | +5,000 | $4.52 | $22.60K | 5,000 |
| Christopher U. Missling President and CEO, Director | Mar 28, 2024 | Option exercise | +73,380 | $1.32 | $96.86K | 1,323,590 |
| Christopher U. Missling President and CEO, Director | Mar 28, 2024 | Sale | −73,380 | $5.11 | $374.97K | 1,250,210 |
| Christopher U. Missling President and CEO, Director | Jun 29, 2023 | Option exercise | +232,000 | $1.60 | $371.20K | 1,250,210 |
| Christopher U. Missling President and CEO, Director | Jun 28, 2023 | Option exercise | +268,000 | $1.60 | $428.80K | 1,286,210 |
| Christopher U. Missling President and CEO, Director | Jun 28, 2023 | Sale | −268,000 | $7.98 | $2.14M | 1,018,210 |
| Athanasios Skarpelos Director | May 25, 2022 | Sale | −50,000 | $9.06 | $453.00K | 1,306,458 |
| Athanasios Skarpelos Director | May 25, 2022 | Option exercise | +50,000 | $0.92 | $46.00K | 1,356,458 |
| Christopher U. Missling President and CEO, Director | Jun 29, 2021 | Option exercise | +51,620 | $1.32 | $68.14K | 1,069,830 |
| Christopher U. Missling President and CEO, Director | Jun 29, 2021 | Sale | −51,620 | $26.00 | $1.34M | 1,018,210 |
| Sandra Boenisch PFO and Treasurer | Jun 29, 2021 | Option exercise | +25,000 | $5.68 | $142.00K | 47,963 |
| Sandra Boenisch PFO and Treasurer | Jun 29, 2021 | Option exercise | +106,696 | $3.28 | $349.96K | 154,659 |
| Sandra Boenisch PFO and Treasurer | Jun 29, 2021 | Option exercise | +35,000 | $5.92 | $207.20K | 189,659 |
| Sandra Boenisch PFO and Treasurer | Jun 29, 2021 | Sale | −166,696 | $26.53 | $4.42M | 22,963 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $4.90 | $7.35K | 92,000 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +50,000 | $2.96 | $148.00K | 145,000 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $6.11 | $9.17K | 95,000 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $5.66 | $8.49K | 93,500 |
| Elliot Favus Director | May 21, 2021 | Sale | −145,000 | $11.70 | $1.70M | 0 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $5.57 | $8.36K | 90,500 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $5.64 | $8.46K | 89,000 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +50,000 | $0.92 | $46.00K | 87,500 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +37,500 | $1.20 | $45.00K | 37,500 |
| Peter D.O. Donhauser Director | May 17, 2021 | Buy | +1,000 | $10.93 | $10.93K | 2,165 |
| Elliot Favus Director | Feb 24, 2021 | Option exercise | +45,500 | $2.58 | $117.39K | 45,000 |
| Elliot Favus Director | Feb 24, 2021 | Option exercise | +100,000 | $3.28 | $328.00K | 145,000 |
| Elliot Favus Director | Feb 24, 2021 | Sale | −145,500 | $12.66 | $1.84M | 0 |
| Peter D.O. Donhauser Director | Feb 19, 2021 | Buy | +165 | $12.97 | $2.14K | 1,165 |
| Peter D.O. Donhauser Director | Feb 19, 2021 | Buy | +1,000 | $12.62 | $12.62K | 1,000 |
| Christopher U. Missling President and CEO, Director | Mar 7, 2018 | Buy | +1,360 | $2.92 | $3.97K | 1,018,210 |
| Christopher U. Missling President and CEO, Director | Mar 6, 2018 | Buy | +1,450 | $2.73 | $3.96K | 1,016,850 |
| Christopher U. Missling President and CEO, Director | Mar 5, 2018 | Buy | +1,500 | $2.63 | $3.95K | 1,015,400 |
| Christopher U. Missling Director, President & CEO | Mar 2, 2018 | Buy | +1,650 | $2.41 | $3.98K | 1,013,900 |
| Christopher U. Missling President and CEO, Director | Oct 25, 2017 | Buy | +375 | $4.39 | $1.65K | 1,012,250 |
| Christopher U. Missling President and CEO, Director | Oct 24, 2017 | Buy | +375 | $4.92 | $1.85K | 1,011,875 |
| Christopher U. Missling President and CEO, Director | Oct 19, 2017 | Buy | +375 | $4.49 | $1.68K | 1,011,500 |
| Christopher U. Missling President and CEO, Director | Oct 17, 2017 | Buy | +375 | $4.27 | $1.60K | 1,011,125 |
| Christopher U. Missling President and CEO, Director | Oct 13, 2017 | Buy | +750 | $4.22 | $3.17K | 1,010,750 |
| Christopher U. Missling President and CEO, Director | Oct 5, 2017 | Buy | +375 | $4.30 | $1.61K | 1,010,000 |
| Christopher U. Missling President and CEO, Director | Oct 2, 2017 | Buy | +375 | $4.20 | $1.58K | 1,009,625 |
| Christopher U. Missling President and CEO, Director | Sep 28, 2017 | Buy | +375 | $4.21 | $1.58K | 1,009,250 |
| Christopher U. Missling President and CEO, Director | Sep 26, 2017 | Buy | +375 | $3.88 | $1.46K | 1,008,875 |
| Christopher U. Missling President and CEO, Director | Sep 20, 2017 | Buy | +375 | $4.23 | $1.59K | 1,008,500 |
| Christopher U. Missling President and CEO, Director | Sep 18, 2017 | Buy | +375 | $4.40 | $1.65K | 1,008,125 |
| Christopher U. Missling President and CEO, Director | Sep 14, 2017 | Buy | +375 | $4.58 | $1.72K | 1,007,750 |
| Christopher U. Missling President and CEO, Director | Sep 11, 2017 | Buy | +375 | $4.81 | $1.80K | 1,007,375 |
| Christopher U. Missling President and CEO, Director | Sep 7, 2017 | Buy | +375 | $4.76 | $1.79K | 1,007,000 |
| Christopher U. Missling President and CEO, Director | Sep 5, 2017 | Buy | +375 | $4.90 | $1.84K | 1,006,625 |
| Christopher U. Missling President and CEO, Director | Aug 31, 2017 | Buy | +375 | $4.48 | $1.68K | 1,006,250 |
| Christopher U. Missling President and CEO, Director | Aug 28, 2017 | Buy | +375 | $4.44 | $1.67K | 1,005,875 |
| Christopher U. Missling President and CEO, Director | Aug 24, 2017 | Buy | +375 | $4.54 | $1.70K | 1,005,500 |
| Christopher U. Missling President and CEO, Director | Aug 21, 2017 | Buy | +375 | $4.07 | $1.53K | 1,005,125 |
| Christopher U. Missling President and CEO, Director | Aug 18, 2017 | Buy | +375 | $3.81 | $1.43K | 1,004,750 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Anavex Life Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 38,689 shares on Sep 22, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christopher U. Missling Officer | Mar 28, 2024 | 73,380 | $371.30K | Mar 28, 2024 | Exercised Stock Options |
| Christopher U. Missling Officer | Jun 28, 2023 | 268,000 | $2.14M | Jun 28, 2023 | Stock Option Exercise |
Congress trades
2 trades in Anavex Life Sciences reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Sold | Dec 12, 2022 | $1K–15K | Jan 20, 2023 |
| Christopher L. Jacobs NY27 | Bought | Oct 12, 2022 | $1K–15K | Nov 16, 2022 |
See a number that looks wrong?